Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.

AbCellera, a Canada-based developer of an antibody drug discovery platform based on University of British Columbia research, floated on the Nasdaq Global Select Market on Friday in a $483m initial public offering that also provided an exit to University of Minnesota. The company priced just over 24.1 million shares, upsized from 23 million, at $20…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.